Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
USM | Ann: USM NTA 03-10-2024 $8.07624 | 07:32 | 0 | 20 | |||
|
|||||||
USM | Ann: USM NTA 02-10-2024 $8.03847 | 03/10/24 | 0 | 27 | |||
|
|||||||
USM | Ann: USM NTA 01-10-2024 $7.99254 | 02/10/24 | 0 | 33 | |||
|
|||||||
USM | Ann: USM NTA 30-09-2024 $7.96853 | 01/10/24 | 0 | 33 | |||
|
|||||||
USM | Ann: USM NTA 27-09-2024 $8.00786 | 30/09/24 | 0 | 39 | |||
|
|||||||
USM | Ann: USM NTA 26-09-2024 $8.01292 | 27/09/24 | 0 | 42 | |||
|
|||||||
USM | Ann: USM NTA 25-09-2024 $8.00687 | 26/09/24 | 0 | 35 | |||
|
|||||||
USM | Ann: USM NTA 24-09-2024 $8.06048 | 25/09/24 | 0 | 49 | |||
|
See All Discussions